Zyprexa

Country: European Union

Language: English

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

olanzapine

Available from:

Eli Lilly Nederland B.V.

ATC code:

N05AH03

INN (International Name):

olanzapine

Therapeutic group:

Psycholeptics

Therapeutic area:

Schizophrenia; Bipolar Disorder

Therapeutic indications:

Coated tabletsAdultsOlanzapine is indicated for the treatment of schizophrenia.Olanzapine is effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response.Olanzapine is indicated for the treatment of moderate to severe manic episode.In patients whose manic episode has responded to olanzapine treatment, olanzapine is indicated for the prevention of recurrence in patients with bipolar disorder.InjectionAdultsZyprexa powder for solution for injection is indicated for the rapid control of agitation and disturbed behaviours in patients with schizophrenia or manic episode, when oral therapy is not appropriate. Treatment with Zyprexa powder for solution for injection should be discontinued and the use of oral olanzapine should be initiated as soon as clinically appropriate.

Product summary:

Revision: 42

Authorization status:

Authorised

Authorization date:

1996-09-27

Patient Information leaflet

                                60
B. PACKAGE LEAFLET
61
PACKAGE LEAFLET: INFORMATION FOR THE USER
ZYPREXA 2.5 MG COATED TABLETS
ZYPREXA 5 MG COATED TABLETS
ZYPREXA 7.5 MG COATED TABLETS
ZYPREXA 10 MG COATED TABLETS
ZYPREXA 15 MG COATED TABLETS
ZYPREXA 20 MG COATED TABLETS
olanzapine
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
•
Keep this leaflet. You may need to read it again.
•
If you have any further questions, ask your doctor or pharmacist.
•
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
•
If you get any side effects talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What ZYPREXA is and what it is used for
2.
What you need to know before you take ZYPREXA
3.
How to take ZYPREXA
4.
Possible side effects
5.
How to store ZYPREXA
6.
Contents of the pack and other information
1.
WHAT ZYPREXA IS AND WHAT IT IS USED FOR
ZYPREXA contains the active substance olanzapine. ZYPREXA belongs to a
group of medicines
called antipsychotics and is used to treat the following conditions:
•
Schizophrenia, a disease with symptoms such as hearing, seeing or
sensing things which are not
there, mistaken beliefs, unusual suspiciousness, and becoming
withdrawn. People with this
disease may also feel depressed, anxious or tense.
•
Moderate to severe manic episodes, a condition with symptoms of
excitement or euphoria.
ZYPREXA has been shown to prevent recurrence of these symptoms in
patients with bipolar disorder
whose manic episode has responded to olanzapine treatment.
2.
WHAT YOU NEED TO KNOW BEFORE YOU TAKE ZYPREXA
_ _
DO NOT TAKE ZYPREXA
•
If you are allergic (hypersensitive) to olanzapine or any of the other
ingredients of this medicine
(listed in section 6).
An allergic reaction may be recognised as a rash, itching, a swollen
face,
swollen lips or shortness of breath. If this 
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
ZYPREXA 2.5 mg coated tablets
ZYPREXA 5 mg coated tablets
ZYPREXA 7.5 mg coated tablets
ZYPREXA 10 mg coated tablets
ZYPREXA 15 mg coated tablets
ZYPREXA 20 mg coated tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
ZYPREXA 2.5 mg coated tablets
Each coated tablet contains 2.5 mg olanzapine.
Excipient with known effect: Each coated tablet contains 102 mg
lactose monohydrate.
ZYPREXA 5 mg coated tablets
Each coated tablet contains 5 mg olanzapine.
Excipient with known effect: Each coated tablet contains 156 mg
lactose monohydrate.
ZYPREXA 7.5 mg coated tablets
Each coated tablet contains 7.5 mg olanzapine.
Excipient with known effect: Each coated tablet contains 234 mg
lactose monohydrate.
ZYPREXA 10 mg coated tablets
Each coated tablet contains 10 mg olanzapine.
Excipient with known effect: Each coated tablet contains 312 mg
lactose monohydrate.
ZYPREXA 15 mg coated tablets
Each coated tablet contains 15 mg olanzapine.
Excipient with known effect: Each coated tablet contains 178 mg
lactose monohydrate.
ZYPREXA 20 mg coated tablets
Each coated tablet contains 20 mg olanzapine.
Excipient with known effect: Each coated tablet conatins 238 mg
lactose monohydrate.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Coated tablet
ZYPREXA 2.5 mg coated tablets
Round, white, coated tablets
_ _
imprinted with “LILLY” and a numeric identicode “4112”.
ZYPREXA 5 mg coated tablets
Round, white, coated tablets
_ _
imprinted with “LILLY” and a numeric identicode “4115”.
ZYPREXA 7.5 mg coated tablets
Round, white, coated tablets
_ _
imprinted with “LILLY” and a numeric identicode “4116”.
3
ZYPREXA 10 mg coated tablets
Round, white, coated tablets
_ _
imprinted with “LILLY” and a numeric identicode “4117”.
ZYPREXA 15 mg coated tablets
Elliptical, blue, coated tablets
_ _
debossed with “LILLY” and a numeric identicode “4415”.
ZYPREXA 20 mg coated tablets
Pink, elliptical, coated tablets
_ 
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 26-02-2024
Summary of Product characteristics Summary of Product characteristics Bulgarian 26-02-2024
Public Assessment Report Public Assessment Report Bulgarian 03-07-2013
Patient Information leaflet Patient Information leaflet Spanish 26-02-2024
Public Assessment Report Public Assessment Report Spanish 03-07-2013
Patient Information leaflet Patient Information leaflet Czech 26-02-2024
Public Assessment Report Public Assessment Report Czech 03-07-2013
Patient Information leaflet Patient Information leaflet Danish 26-02-2024
Public Assessment Report Public Assessment Report Danish 03-07-2013
Patient Information leaflet Patient Information leaflet German 26-02-2024
Public Assessment Report Public Assessment Report German 03-07-2013
Patient Information leaflet Patient Information leaflet Estonian 26-02-2024
Public Assessment Report Public Assessment Report Estonian 03-07-2013
Patient Information leaflet Patient Information leaflet Greek 26-02-2024
Public Assessment Report Public Assessment Report Greek 03-07-2013
Patient Information leaflet Patient Information leaflet French 26-02-2024
Public Assessment Report Public Assessment Report French 03-07-2013
Patient Information leaflet Patient Information leaflet Italian 26-02-2024
Public Assessment Report Public Assessment Report Italian 03-07-2013
Patient Information leaflet Patient Information leaflet Latvian 26-02-2024
Public Assessment Report Public Assessment Report Latvian 03-07-2013
Patient Information leaflet Patient Information leaflet Lithuanian 26-02-2024
Summary of Product characteristics Summary of Product characteristics Lithuanian 26-02-2024
Public Assessment Report Public Assessment Report Lithuanian 03-07-2013
Patient Information leaflet Patient Information leaflet Hungarian 26-02-2024
Summary of Product characteristics Summary of Product characteristics Hungarian 26-02-2024
Public Assessment Report Public Assessment Report Hungarian 03-07-2013
Patient Information leaflet Patient Information leaflet Maltese 26-02-2024
Public Assessment Report Public Assessment Report Maltese 03-07-2013
Patient Information leaflet Patient Information leaflet Dutch 26-02-2024
Public Assessment Report Public Assessment Report Dutch 03-07-2013
Patient Information leaflet Patient Information leaflet Polish 26-02-2024
Public Assessment Report Public Assessment Report Polish 03-07-2013
Patient Information leaflet Patient Information leaflet Portuguese 26-02-2024
Summary of Product characteristics Summary of Product characteristics Portuguese 26-02-2024
Public Assessment Report Public Assessment Report Portuguese 03-07-2013
Patient Information leaflet Patient Information leaflet Romanian 26-02-2024
Public Assessment Report Public Assessment Report Romanian 03-07-2013
Patient Information leaflet Patient Information leaflet Slovak 26-02-2024
Public Assessment Report Public Assessment Report Slovak 03-07-2013
Patient Information leaflet Patient Information leaflet Slovenian 26-02-2024
Summary of Product characteristics Summary of Product characteristics Slovenian 26-02-2024
Public Assessment Report Public Assessment Report Slovenian 03-07-2013
Patient Information leaflet Patient Information leaflet Finnish 26-02-2024
Public Assessment Report Public Assessment Report Finnish 03-07-2013
Patient Information leaflet Patient Information leaflet Swedish 26-02-2024
Public Assessment Report Public Assessment Report Swedish 03-07-2013
Patient Information leaflet Patient Information leaflet Norwegian 26-02-2024
Summary of Product characteristics Summary of Product characteristics Norwegian 26-02-2024
Patient Information leaflet Patient Information leaflet Icelandic 26-02-2024
Summary of Product characteristics Summary of Product characteristics Icelandic 26-02-2024
Patient Information leaflet Patient Information leaflet Croatian 26-02-2024

Search alerts related to this product

View documents history